Neurocrine Biosciences Says Ingrezza Shows Greater Potency Than Austedo

MT Newswires Live01-15

Neurocrine Biosciences (NBIX) said Thursday it presented head-to-head data showing Ingrezza delivered greater potency compared with Teva Pharmaceutical's (TEVA) Austedo XR after a single dose of treatment for involuntary movement disorders.

The company said Ingrezza capsules achieved "significantly higher" vesicular monoamine transporter 2 target occupancy, which measures drug response level in involuntary movement disorders, including tardive dyskinesia and Huntington's disease chorea.

All doses of both Ingrezza and Austedo XR were generally well-tolerated and consistent with their safety profiles, Neurocrine said.

Shares of Neurocrine were down more than 1% in recent trading Thursday.

Price: 133.88, Change: -1.46, Percent Change: -1.08

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603632989?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603632989","market":"sh","top_or_hot":-1,"title":"Neurocrine Biosciences Says Ingrezza Shows Greater Potency Than Austedo","media":"MT Newswires Live","content":"<html><body><p> Neurocrine Biosciences (NBIX) said Thursday it presented head-to-head data showing Ingrezza delivered greater potency compared with <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical's (TEVA) Austedo XR after a single dose of treatment for involuntary movement disorders.</p><p>The company said Ingrezza capsules achieved \"significantly higher\" vesicular monoamine transporter 2 target occupancy, which measures drug response level in involuntary movement disorders, including tardive dyskinesia and Huntington's disease chorea.</p><p>All doses of both Ingrezza and Austedo XR were generally well-tolerated and consistent with their safety profiles, Neurocrine said.</p><p>Shares of Neurocrine were down more than 1% in recent trading Thursday.</p><p>Price: 133.88, Change: -1.46, Percent Change: -1.08</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine Biosciences Says Ingrezza Shows Greater Potency Than Austedo</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine Biosciences Says Ingrezza Shows Greater Potency Than Austedo\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-15 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Neurocrine Biosciences (NBIX) said Thursday it presented head-to-head data showing Ingrezza delivered greater potency compared with <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical's (TEVA) Austedo XR after a single dose of treatment for involuntary movement disorders.</p><p>The company said Ingrezza capsules achieved \"significantly higher\" vesicular monoamine transporter 2 target occupancy, which measures drug response level in involuntary movement disorders, including tardive dyskinesia and Huntington's disease chorea.</p><p>All doses of both Ingrezza and Austedo XR were generally well-tolerated and consistent with their safety profiles, Neurocrine said.</p><p>Shares of Neurocrine were down more than 1% in recent trading Thursday.</p><p>Price: 133.88, Change: -1.46, Percent Change: -1.08</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603632989","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603632989","pubTimestamp":1768489280,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neurocrine Biosciences  said Thursday it presented head-to-head data showing Ingrezza delivered greater potency compared with Teva Pharmaceutical's  Austedo XR after a single dose of treatment for involuntary movement disorders.The company said Ingrezza capsules achieved \"significantly higher\" vesicular monoamine transporter 2 target occupancy, which measures drug response level in involuntary movement disorders, including tardive dyskinesia and Huntington's disease chorea.All doses of both Ingrezza and Austedo XR were generally well-tolerated and consistent with their safety profiles, Neurocrine said.Shares of Neurocrine were down more than 1% in recent trading Thursday.Price: 133.88, Change: -1.46, Percent Change: -1.08","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4559":"巴菲特持仓","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","TEVA":"梯瓦制药","BK4139":"生物科技","NBIX":"神经分泌生物科学","BK4007":"制药","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4566":"资本集团","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4557":"大麻股","BK4596":"哈里斯概念","BK4588":"碎股","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4584":"避孕概念"},"translate_title":"Neurocrine Biosciences表示Ingrezza比Austedo表现出更大的效力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1.5,"TEVA":1},"content_text":"Neurocrine Biosciences (NBIX) said Thursday it presented head-to-head data showing Ingrezza delivered greater potency compared with Teva Pharmaceutical's (TEVA) Austedo XR after a single dose of treatment for involuntary movement disorders.The company said Ingrezza capsules achieved \"significantly higher\" vesicular monoamine transporter 2 target occupancy, which measures drug response level in involuntary movement disorders, including tardive dyskinesia and Huntington's disease chorea.All doses of both Ingrezza and Austedo XR were generally well-tolerated and consistent with their safety profiles, Neurocrine said.Shares of Neurocrine were down more than 1% in recent trading Thursday.Price: 133.88, Change: -1.46, Percent Change: -1.08","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603632989","isCrawlerRequest":true}